Cantor Fitzgerald Downgrades Tonix Pharma (TNXP) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts TNXP Hot Sheet
Price: $6.40 --0%
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 7 | New: 26
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 7 | New: 26
Join SI Premium – FREE
Cantor Fitzgerald downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Hold with a price target of $1.00 (from $5.00).
For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.
Shares of Tonix Pharma closed at $0.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Double Upgrades CarMax (KMX) to Buy
- Evolution Mining Ltd. (EVN:AU) (CAHPF) PT Lowered to AUD15.70 at UBS
- Rio Tinto Ltd. (RIO:AU) (RIO) PT Lowered to AUD171 at UBS
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
